⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 5, 2024Open Access

Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Zhanfang Guo Jingqin Luo R. Jay Mashl Jeremy Hoog Piyush Maiti Nikki Fettig Sherri R. Davies Rebecca Aft Jason M. Held Ramaswamy Govindan Li Ding Shunqiang Li Cornelius von Morze Gerburg M. Wulf Kooresh I. Shoghi X. Cynthia

View Full Paper

Ask AI

Bookmark

Share

Abstract

Tumor growth response to eribulin and copanlisib, either alone or in combination, in additional TNBC PDX models

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/68e660cfb6db6435875eed78 https://doi.org/10.1158/2767-9764.25976510

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
2Supplementary Figure S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
3Supplementary Figure S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
4Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
5Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024

More related papers

Supplementary Figure S2 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
Supplementary Figure S2 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
FIGURE 3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024